Market Closed -
Toronto S.E.
01:09:13 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.065
CAD
|
-7.14%
|
|
+8.33%
|
-45.83%
|
Fiscal Period: Oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
17.04
|
98.44
|
56.58
|
46.61
|
32.73
|
21.44
|
Enterprise Value (EV)
1 |
19.21
|
96.26
|
56.28
|
46.68
|
32.77
|
23.05
|
P/E ratio
|
-12.8
x
|
-19.7
x
|
-13.7
x
|
-19.9
x
|
-8.81
x
|
-8.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.3
x
|
725
x
|
535
x
|
174
x
|
48.7
x
|
616
x
|
EV / Revenue
|
15
x
|
709
x
|
532
x
|
174
x
|
48.8
x
|
663
x
|
EV / EBITDA
|
-28.5
x
|
-
|
-14.1
x
|
-22
x
|
-9.7
x
|
-10
x
|
EV / FCF
|
-227
x
|
-54.8
x
|
-86.5
x
|
-37.8
x
|
-34.8
x
|
-57.6
x
|
FCF Yield
|
-0.44%
|
-1.83%
|
-1.16%
|
-2.64%
|
-2.88%
|
-1.74%
|
Price to Book
|
-7.53
x
|
45.5
x
|
1,196
x
|
-488
x
|
153
x
|
-8.58
x
|
Nbr of stocks (in thousands)
|
179,326
|
221,222
|
226,309
|
233,045
|
251,732
|
252,224
|
Reference price
2 |
0.0950
|
0.4450
|
0.2500
|
0.2000
|
0.1300
|
0.0850
|
Announcement Date
|
3/4/19
|
3/2/20
|
3/3/21
|
2/28/22
|
2/28/23
|
2/28/24
|
Fiscal Period: Oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.279
|
0.1357
|
0.1057
|
0.268
|
0.6719
|
0.0348
|
EBITDA
1 |
-0.6728
|
-
|
-3.985
|
-2.125
|
-3.38
|
-2.303
|
EBIT
1 |
-0.8563
|
-4.199
|
-3.995
|
-2.134
|
-3.39
|
-2.313
|
Operating Margin
|
-66.96%
|
-3,093.19%
|
-3,779.24%
|
-796.37%
|
-504.45%
|
-6,649.66%
|
Earnings before Tax (EBT)
1 |
-1.153
|
-4.556
|
-4.141
|
-2.312
|
-3.552
|
-2.544
|
Net income
1 |
-1.273
|
-4.55
|
-4.134
|
-2.306
|
-3.558
|
-2.543
|
Net margin
|
-99.57%
|
-3,351.61%
|
-3,910.4%
|
-860.5%
|
-529.5%
|
-7,312.43%
|
EPS
2 |
-0.007412
|
-0.0226
|
-0.0183
|
-0.0101
|
-0.0148
|
-0.0101
|
Free Cash Flow
1 |
-0.0846
|
-1.758
|
-0.6504
|
-1.234
|
-0.9425
|
-0.4001
|
FCF margin
|
-6.61%
|
-1,295.08%
|
-615.28%
|
-460.35%
|
-140.27%
|
-1,150.34%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/19
|
3/2/20
|
3/3/21
|
2/28/22
|
2/28/23
|
2/28/24
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2.17
|
-
|
-
|
0.07
|
0.05
|
1.61
|
Net Cash position
1 |
-
|
2.19
|
0.29
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-3.226
x
|
-
|
-
|
-0.0338
x
|
-0.0142
x
|
-0.6994
x
|
Free Cash Flow
1 |
-0.08
|
-1.76
|
-0.65
|
-1.23
|
-0.94
|
-0.4
|
ROE (net income / shareholders' equity)
|
59.2%
|
12,739%
|
-370%
|
9,296%
|
-6,056%
|
221%
|
ROA (Net income/ Total Assets)
|
-52.9%
|
-104%
|
-78.1%
|
-77.9%
|
-164%
|
-124%
|
Assets
1 |
2.405
|
4.358
|
5.293
|
2.96
|
2.165
|
2.043
|
Book Value Per Share
2 |
-0.0100
|
0.0100
|
0
|
-0
|
0
|
-0.0100
|
Cash Flow per Share
2 |
0
|
0.0200
|
0.0100
|
0
|
0
|
0
|
Capex
|
-
|
-
|
0.05
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
44.43%
|
-
|
-
|
-
|
Announcement Date
|
3/4/19
|
3/2/20
|
3/3/21
|
2/28/22
|
2/28/23
|
2/28/24
|
|
1st Jan change
|
Capi.
|
---|
| -45.83% | 12.18M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|